· 1 source · Verified

RougeTx Launches With $58M Series A for Rare Vascular Disease

RougeTx launched with $58 million to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia and expand its vascular-biology platform.

By Venture Capital Tracker

Editorial team

Share
RougeTx Series A $58M

RougeTx has launched with a $58 million Series A to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder.

Deal details & investors

Funding event

RougeTx

$58M Series A

Led by BioGeneration Ventures , Angelini Ventures +1 more

The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. An EIB co-investment facility also supports the financing through Angelini Ventures.

What RougeTx is targeting

RougeTx is focused on vascular instability linked to pericyte dysfunction. Its lead program is intended as a once-daily oral treatment for HHT, while the company's periSCOPE platform is designed to identify additional diseases where restoring vascular stability could be therapeutically useful.

Why the Series A is notable

The company is entering the market with a large early-stage round before clinical proof. That is typical of platform biotech only when investors believe the underlying biology can support more than one asset.

The main milestones are therefore scientific: preclinical validation, toxicology, manufacturing readiness and a credible path into first-in-human studies. If the HHT program works, the platform claim becomes more valuable; if it fails, the breadth of the periSCOPE thesis will be tested quickly.

Follow Venture Capital Tracker on Google

Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.

Add as preferred source

By Venture Capital Tracker

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

Related articles

See all

Frequently Asked Questions

Direct answers to common questions about this topic

Sources & references

1 source

Reporting and documents referenced in this article.

  1. RougeTx — Series A announcement

Companies and investors in this story

Explore their profiles or save them for later.

View watchlist
Back to Blog